Amneal Pharmaceuticals Inc (NYSE:AMRX) – Analysts at Leerink Swann cut their FY2018 EPS estimates for Amneal Pharmaceuticals in a note issued to investors on Wednesday, November 7th. Leerink Swann analyst A. Fadia now anticipates that the company will post earnings per share of $0.91 for the year, down from their previous forecast of $0.95. Leerink Swann also issued estimates for Amneal Pharmaceuticals’ Q4 2018 earnings at $0.26 EPS, FY2019 earnings at $1.38 EPS, FY2020 earnings at $1.55 EPS, FY2021 earnings at $1.82 EPS and FY2022 earnings at $2.03 EPS.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Wednesday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $476.50 million for the quarter, compared to the consensus estimate of $486.01 million. Amneal Pharmaceuticals had a negative net margin of 36.54% and a positive return on equity of 4.98%. The firm’s quarterly revenue was up 87.1% compared to the same quarter last year.

A number of other analysts also recently weighed in on the stock. Royal Bank of Canada upgraded shares of Amneal Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research report on Monday, August 13th. ValuEngine cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 27th. Morgan Stanley initiated coverage on Amneal Pharmaceuticals in a research note on Monday, July 23rd. They set an “overweight” rating and a $22.00 target price for the company. Canaccord Genuity reissued a “hold” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Tuesday, September 4th. Finally, SunTrust Banks cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 target price for the company. in a research note on Tuesday, October 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $22.75.

Shares of NYSE:AMRX opened at $19.27 on Monday. The company has a market capitalization of $5.89 billion, a P/E ratio of 30.59, a PEG ratio of 0.97 and a beta of 1.56. The company has a debt-to-equity ratio of 2.92, a quick ratio of 1.26 and a current ratio of 1.91. Amneal Pharmaceuticals has a fifty-two week low of $13.47 and a fifty-two week high of $24.48.

Institutional investors and hedge funds have recently modified their holdings of the company. DekaBank Deutsche Girozentrale bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $101,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $116,000. SG Americas Securities LLC bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $120,000. Neuburgh Advisers LLC bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $123,000. Finally, Great West Life Assurance Co. Can bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $130,000. 32.25% of the stock is owned by institutional investors.

In other news, SVP Nikita Shah sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total transaction of $1,173,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bryan M. Reasons sold 11,698 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Featured Article: What is the NASDAQ?

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.